Navigating data management challenges in the pharmaceutical life cycle

Artificial intelligence is changing how pharmaceutical companies operate, how they develop and study new treatments, and even what form those treatments take. Pharma companies are now pairing medicines with software — so-called digiceuticals powered by virtual reality and AI. Most of the world’s largest drug companies now have a technology officer in their C-suites. And AI is now being used to help find new drug targets, model diseases, and make clinical trials more efficient.

When it comes to the Pharma supply chain, problems can occur at any part of the process, including non-standardized bills of material, translation mistakes, typos and poor proofreading, missed annotations, unclear briefs, artwork problems, expired digital assets, third-party artwork suppliers and printing shops. Consumer and pharma companies must also deal with a very strict regulatory environment. Each time there is a problem, the manufacturer risks having to issue a (potentially major) recall.

Osteosarcoma is the most common type of primary bone cancer affecting adolescents and children attributed to rapid bone growth and turnover with a peak incidence at 18 years old. it is a rare incurable and often fatal disease. The current osteosarcoma treatments include standard chemotherapy, limb salvage surgery or amputation. The 5-year relative survival rate is 70% for localized forms, however, metastasis is present in about one fifth to one-quarter of patients at diagnosis, which then contributes to a 5-year survival rate of around 20%. The survival statistics have remained constant with no advances in treatment options for decades highlighting the need for new therapeutic options.

In association with pharmaphorum, Tag discusses what pharmaceutical marketers can to do stay ahead of the evolving customer journey.